Please assess the completion status of the following clinical trial:

Trial Title: Evaluating an Ebola and a Marburg Vaccine in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Available for clinical follow-up through Week 104~* Willing to have photo taken for identification purposes~* Willing to be taken home at enrollment visit and allow home visits if appointments are not kept~* Completes an Assessment of Understanding (AoU) prior to enrollment by answering 9 out of 10 questions at least once in 3 attempts~* In good general health without clinically significant medical history~* Has a physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment~* Female participants of reproductive potential must have a negative result on a human choriogonadotropin (β-HCG) pregnancy test~* Female participants must either be incapable of becoming pregnant or agree to take appropriate precautions that pregnancy will not occur during the first 24 weeks of the study~Exclusion Criteria:~* Pregnant, breast-feeding, or planning to become pregnant during the first 24 weeks after enrollment~* History of Ebola or Marburg virus exposure~* Occupational health risk of exposure to the Ebola or Marburg virus known to be higher than that of the general population~* Has received any of the following substances:~  * Investigational Ebola or Marburg vaccine in a prior clinical trial~ * Blood products within 120 days prior to HIV screening~ * Immunoglobulin within 60 days of prior to HIV screening~ * Live attenuated vaccines within 30 days prior to initial study vaccine administration~ * Investigational research agents within 30 days prior to initial study vaccine administration~ * Medically indicated subunit or killed vaccines (such as influenza, pneumococcal, or allergy treatment with antigen injections) within 14 days of study vaccine administration~ * Current anti-tuberculosis prophylaxis or therapy~ * Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within 12 weeks of enrollment, except in the following cases: use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroids for a non-chronic condition (based on investigator clinical judgement) at least 2 weeks prior to enrollment in this study~* History of serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain~* Presence of idiopathic urticaria within the past 2 years~* History of autoimmune disease or immunodeficiency~* History of unstable asthma; asthma that required emergent care, urgent care, hospitalization or intubation during the past 2 years; or asthma that requires the use of oral or parenteral corticosteroids~* History of diabetes mellitus (type I or II), with the exception of a history of gestational diabetes~* History of thyroidectomy or thyroid disease that required medication within the past 12 months~* History of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema~* History of hypertension that is not well controlled by medication or blood pressure that is more than 145/95 mm Hg at enrollment~* Presence of a bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with intramuscular injections or blood draws, or routine use of anticoagulant medications~* Presence of active malignancy, treated malignancy for which there is not reasonable assurance of sustained cure, or malignancy that is likely to recur during the period of the study~* History of a seizure or seizure disorder~* Asplenia, functional asplenia, or any condition resulting in the absence or removal of the spleen~* Allergic reaction to aminoglycoside antibiotics~* Presence of a psychiatric condition that precludes compliance with the protocol~* History of psychoses, bipolar disorder, disorder requiring lithium, or suicide plan or attempt within 5 years prior to enrollment~* Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent~* Evidence of syphilis based on history, exam, and rapid plasma reagin (RPR) test results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Ebola vaccine only (Type: EXPERIMENTAL): Participants will receive only the Ebola vaccine or a placebo injection.
- Marburg vaccine only (Type: EXPERIMENTAL): Participants will receive only the Marburg vaccine or a placebo injection.
- Ebola and Marburg vaccine (Type: EXPERIMENTAL): Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).